【レポートの概要（一部）】
Introduction 15
Drug Eluting Stents (DES) Overview 15
Products under Development 16
Drug Eluting Stents (DES) – Pipeline Products by Stage of Development 16
Drug Eluting Stents (DES) – Pipeline Products by Segment 17
Drug Eluting Stents (DES) – Pipeline Products by Territory 18
Drug Eluting Stents (DES) – Pipeline Products by Regulatory Path 19
Drug Eluting Stents (DES) – Pipeline Products by Estimated Approval Date 20
Drug Eluting Stents (DES) – Ongoing Clinical Trials 21
Drug Eluting Stents (DES) – Pipeline Products under Development by Companies 22
Drug Eluting Stents (DES) Companies – Pipeline Products by Stage of Development 22
Drug Eluting Stents (DES) – Pipeline Products by Stage of Development 24
Drug Eluting Stents (DES) Companies and Product Overview 27
Abbott Vascular Inc. Company Overview 27
Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview 27
Abbott Vascular Inc. – Ongoing Clinical Trials Overview 29
Absorb Bioresorbable Vascular Scaffold Clinical Trial Details 31
AlviMedica Medical Technologies Inc. Company Overview 40
AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
AlviMedica Medical Technologies Inc. – Ongoing Clinical Trials Overview 42
Cre8 DES Clinical Trial Details 43
Amaranth Medical, Inc. Company Overview 45
Amaranth Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
Amaranth Medical, Inc. – Ongoing Clinical Trials Overview 47
FORTITUDE Scaffold Ongoing Clinical Trial Details 48
Next Generation FORTITUDE Scaffold Ongoing Clinical Trial Details 49
Arterius Ltd Company Overview 50
Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
Biosensors International Group, Ltd. Company Overview 51
Biosensors International Group, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 51
Biosensors International Group, Ltd. – Ongoing Clinical Trials Overview 53
BioFreedom Drug Coated Stent Clinical Trial Details 54
Excel II DES Ongoing Clinical Trial Details 55
BioSurfaces, Inc. Company Overview 56
BioSurfaces, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56
Biotronik SE & Co. KG Company Overview 57
Biotronik SE & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 57
Biotronik SE & Co. KG – Ongoing Clinical Trials Overview 60
Orsiro Hybrid Drug Eluting Stent Clinical Trial Details 61
Boston Scientific Corporation Company Overview 62
Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 62
Boston Scientific Corporation – Ongoing Clinical Trials Overview 65
SYNERGY Everolimus-Eluting Stent System Clinical Trial Details 66
CARDIONOVUM GmbH Company Overview 69
CARDIONOVUM GmbH Pipeline Products & Ongoing Clinical Trials Overview 69
CID S.r.l. Company Overview 71
CID S.r.l. Pipeline Products & Ongoing Clinical Trials Overview 71
Contego Medical, LLC Company Overview 73
Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 73
DISA Vascular (Pty) Ltd. Company Overview 74
DISA Vascular (Pty) Ltd. Pipeline Products & Ongoing Clinical Trials Overview 74
Elixir Medical Corporation Company Overview 75
Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 75
Elixir Medical Corporation – Ongoing Clinical Trials Overview 80
DESyne BD Novolimus Eluting Coronary Stent System Ongoing Clinical Trial Details 81
DESyne Nx Novolimus Eluting Coronary Stent System Ongoing Clinical Trial Details 82
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System Ongoing Clinical Trial Details 83
Envision Scientific Pvt. Ltd Company Overview 84
Envision Scientific Pvt. Ltd Pipeline Products & Ongoing Clinical Trials Overview 84
Eurocor GmbH Company Overview 85
Eurocor GmbH Pipeline Products & Ongoing Clinical Trials Overview 85
HangZhou HuaAn Biotechnology Co.,Ltd Company Overview 87
HangZhou HuaAn Biotechnology Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 87
Icon Interventional Systems, Inc. Company Overview 88
Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 88
ICON Medical Corp. Company Overview 89
ICON Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview 89
InspireMD, Inc. Company Overview 90
InspireMD, Inc. Pipeline Products & Ongoing Clinical Trials Overview 90
IRAMED GmbH Company Overview 92
IRAMED GmbH Pipeline Products & Ongoing Clinical Trials Overview 92
Lepu Medical Technology (Beijing) Co., Ltd. Company Overview 95
Lepu Medical Technology (Beijing) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 95
Lepu Medical Technology (Beijing) Co., Ltd. – Ongoing Clinical Trials Overview 97
Nano+ Stent Ongoing Clinical Trial Details 98
Medinol Ltd. Company Overview 99
Medinol Ltd. Pipeline Products & Ongoing Clinical Trials Overview 99
Medinol Ltd. – Ongoing Clinical Trials Overview 100
NIRsupreme Ridaforolimus-Eluting Coronary Stent System Clinical Trial Details 101
Medtronic plc Company Overview 102
Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 102
Meril Life Sciences Pvt. Ltd. Company Overview 104
Meril Life Sciences Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 104
Meril Life Sciences Pvt. Ltd. – Ongoing Clinical Trials Overview 108
BioMime Ongoing Clinical Trial Details 109
Micell Technologies, Inc. Company Overview 110
Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 110
Minvasys Company Overview 112
Minvasys Pipeline Products & Ongoing Clinical Trials Overview 112
NanoCoeur, Inc. Company Overview 114
NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview 114
Northwestern University Company Overview 115
Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 115
OrbusNeich Company Overview 117
OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview 117
OrbusNeich – Ongoing Clinical Trials Overview 119
COMBO Dual Therapy Stent Clinical Trial Details 120
REVA Medical, Inc. Company Overview 122
REVA Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 122
Sino Medical-Device Technology Co., Ltd. Company Overview 125
Sino Medical-Device Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 125
Stentys, SA Company Overview 126
Stentys, SA Pipeline Products & Ongoing Clinical Trials Overview 126
Svelte Medical Systems, Inc. Company Overview 128
Svelte Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 128
Tepha, Inc. Company Overview 130
Tepha, Inc. Pipeline Products & Ongoing Clinical Trials Overview 130
Terumo Corporation Company Overview 131
Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview 131
Terumo Corporation – Ongoing Clinical Trials Overview 134
Ultimaster Ongoing Clinical Trial Details 135
Tryton Medical, Inc. Company Overview 136
Tryton Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 136
University of Strathclyde Company Overview 138
University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview 138
VasoTech Inc. Company Overview 140
VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview 140
Xenogenics Corporation Company Overview 142
Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview 142
Zorion Medical Company Overview 144
Zorion Medical Pipeline Products & Ongoing Clinical Trials Overview 144
Drug Eluting Stents (DES)- Recent Developments 145
Mar 02, 2015: Tryton Medical Announces Publication of Data from Pivotal Trial for Tryton Side Branch Stent in Journal of American College of Cardiology 145
Feb 23, 2015: REVA Bioresorbable Program Update at CRT Conference 146
Feb 19, 2015: BIOTRONIK Advances Clinical Evaluation of Latest Generation DREAMS, World’s First Bioabsorbable Magnesium Scaffold 146
Feb 13, 2015: COMBO Dual Therapy Stent – Three-year Data featured at JIM 2015 147
Feb 12, 2015: Svelte Medical Systems and ASAHI INTECC Announce Manufacturing and Co-Branding Agreements 148
Feb 12, 2015: Biosensors Reports Financial Results for the Third Quarter of Fiscal Year 2015 148
Feb 09, 2015: LEADERS Free Japan Trial Completes Enrollment 150
Feb 04, 2015: Micell Technologies MiStent SES Now Commercially Available in Europe 151
Feb 04, 2015: BIOTRONIK Announces Completion of Patient Enrollment in BIOFLOW-IV Study Evaluating Safety and Efficacy of Orsiro 152
Jan 29, 2015: Abbott Reports Fourth-Quarter 2014 Results 152
Jan 23, 2015: MicroPort Receives CE Mark Approval for Firehawk 155
Jan 20, 2015: Mr. Aurelio Sahagun Promoted to COO of MicroPort Orthopedics 156
Jan 16, 2015: Eurocor Receives CE Mark Approval for E-Magic Plus SES 156
Jan 06, 2015: Biosensors Announces CTO’S Retirement 157
Jan 05, 2015: Acacia Subsidiary Enters into Settlement and Patent License Agreement with Cordis 157
Jan 04, 2015: Firehawk Gains CFDA Approval to Offer More Specifications 157
Dec 11, 2014: COMBO Dual Therapy Stent Healing Benefits Highlighted at GulfPCR-GIM 2014 157
Dec 03, 2014: REVA Implants First Patients With Fantom Scaffold 158
Dec 02, 2014: Terumo receives CE Mark approval for the line extension on Drug-eluting Stent, Ultimaster to advance the treatment of coronary artery disease 159
Nov 19, 2014: New Data From EVOLVE Clinical Program Demonstrate SYNERGY Bioabsorbable Polymer Stent Meets Key Performance Endpoints 159
Nov 12, 2014: Biosensors Reports Financial Results for the Second Quarter and First Half of Fiscal Year 2015 160
Nov 05, 2014: ClearStream Technologies Expands Enniscorthy Facility 162
Nov 04, 2014: Boston Scientific To Host And Webcast Investor Event 163
Nov 03, 2014: Micell Technologies Announces Plans for MiStent SES Commercial Launch 163
Nov 03, 2014: Medtronic Secures CE Mark For Resolute Onyx Drug-eluting Stent 164
Nov 03, 2014: STENTYS Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell To Distribute Its Novel Drug-Eluting Stent 164
Oct 27, 2014: STENTYS’ Sirolimus-Eluting Stent Receives CE Marking 165
Oct 20, 2014: Boston Scientific Initiates Study Of Promus PREMIER Coronary Stent System In Underserved Patient Populations 166
Oct 17, 2014: COMBO Dual Therapy Stent – A Long-term Solution to Vessel Restoration 167
Oct 10, 2014: BIOTRONIK to Offer New Treatment Options in France with Release of Orsiro Drug-Eluting Stent 167
Sep 18, 2014: Latest Data Shows OrbusNeich’s COMBO Dual Therapy Stent has Excellent Healing Benefits 168
Sep 18, 2014: World’s First Integrated Delivery System Meets All Endpoints in the Direct II Randomized, Controlled Drug-Eluting Coronary Stent Study 169
Sep 16, 2014: REVA Presents Fantom Scaffold Program at TCT 2014 Conference 170
Sep 16, 2014: Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014 170
Sep 16, 2014: Amaranth Medical Initiates Clinical Trial of the Second-Generation FORTITUDE Bioresorbable Drug-Eluting Scaffold 171
Sep 15, 2014: Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device 172
Sep 14, 2014: ABSORB II Study Shows Abbott’s Dissolving Heart Device Comparable to the World’s Leading Heart Stent 173
Sep 10, 2014: Tryton Medical Enrolls First U.S. Patient in the EXTENDED ACCESS Registry 174
Sep 10, 2014: Global Bifurcation Leader Tryton Medical Announces Events at TCT 2014 175
Sep 08, 2014: Elixir Medical Announces Schedule of Programs for TCT 2014 176
Sep 04, 2014: Initial Patient Enrolled in BioFreedom USA: First Major American Trial for Biosensors 177
Sep 03, 2014: STENTYS Reaches 10,000 Self-Apposing Stent implantations 178
Sep 01, 2014: BIOSCIENCE Trial Further Confirms Orsiro as Best in Class 178
Sep 01, 2014: Biosensors Welcomes New CEO 179
Aug 06, 2014: Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2015 179
Jul 28, 2014: Tryton Medical Enrolls First Patient in the EXTENDED Access Registry 181
Jul 16, 2014: First patient enrollment in MASCOT registry represents major milestone for COMBO Dual Therapy Stent and OrbusNeich’s clinical program 182
Jul 10, 2014: Abbott Builds Long Term Commitment In China 182
Jul 09, 2014: Micell Technologies Adds to Portfolio of Intellectual Property Protection 183
Jul 09, 2014: STENTYS Expands Marketing of the Self-Apposing Stent in South America 184
Jun 24, 2014: Abbott Announces Job Reductions At Lake County Headquarters In US 184
Jun 17, 2014: Biosensors Leaders Free Japan Trial Enrolls First Patient 185
Jun 12, 2014: First Patient Enrolled in Investigator Initiated REDUCE Study 185
Jun 02, 2014: Stentys Completes Acquisition of Cappella Peel Away from Cappella for USD1.4 Million 186
May 29, 2014: Svelte Medical Systems Announces Completion of 6-Month Follow-up in the DIRECT II Drug-Eluting Stent Study 186
May 28, 2014: Biosensors Reports Financial Results for Fiscal Year 2014 187
May 28, 2014: Biosensors Announces Appointment of New CEO 189
May 27, 2014: STENTYS Self-Apposing Stent Featured Prominently at 2014 EuroPCR Conference 189
May 23, 2014: OrbusNeich Releases Long-term Data for World’s First and Only Dual Therapy Stent 190
May 23, 2014: Micell Technologies Announces Positive Long-Term Data from MiStent SES Clinical Studies Presented at EuroPCR 2014 191
May 23, 2014: Elixir Medical Announces Clinical Trial Results of DESyne BD Novolimus Eluting Coronary Stent System at EuroPCR 192
May 23, 2014: Elixir Medical Announces Results for CE mark-approved DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System at EuroPCR 192
May 23, 2014: Elixir Medical Announces Outstanding Long-Term Clinical Results at EuroPCR for World’s Broadest Portfolio of Three CE Mark-Approved Novolimus Eluting Coronary Intervention Systems 193
May 22, 2014: REVA Holds Sponsored Symposium at EuroPCR 194
May 22, 2014: Complex Lesion BIOFLOW-III Subgroup Analyses Further Support Top Performance of BIOTRONIK Orsiro 194
May 21, 2014: Successful Live Case Demonstration of Elixir Medical’s CE Mark-Approved Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System at EuroPCR 195
May 21, 2014: Boston Scientific Reports Strong Performance Data For SYNERGY Stent System 196
May 21, 2014: Biosensors Leaders Free Patient Population Data Presented at EuroPCR Enrollment Now Complete 196
May 21, 2014: Small Vessel BIOFLOW-II Subgroup Analyses Demonstrate Top Performance of BIOTRONIK Orsiro 197
May 20, 2014: STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients 198
May 15, 2014: Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014 198
May 14, 2014: Elixir Medical to Showcase a Live Case Demonstration of the Breakthrough Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System at EuroPCR 199
May 13, 2014: Elixir Medical’s DESolve 100 Novolimus Eluting Coronary Scaffold System Gets CE Mark 200
May 06, 2014: STENTYS: Journal of the American College of Cardiology Publication Shows Malapposition Influences Death from Early Stent Thrombosis 201
May 05, 2014: USFDA Grants IDE Approval For Biosensors’ BioFreedom US Feasibility Trial 202
May 01, 2014: Boston Scientific Launches Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System In Japan 203
Apr 29, 2014: STENTYS’ Self-Apposing Stent Featured in New Article Published by the Journal of the American College of Cardiology 203
Apr 28, 2014: MicroPort Released New Products to its Nationwide Distributors 204
Apr 10, 2014: Abbott Completes Enrollment of Absorb Randomized Clinical Trials in the United States, Japan and China 204
Mar 28, 2014: Patient Enrollment Completed in Multicenter European REMEDEE Registry of OrbusNeich’s COMBO Dual Therapy Stent 205
Mar 27, 2014: Arterial Remodeling Technologies Enters Into Co-Development Agreement With Terumo For Bioresorbable Scaffold 205
Appendix 207
Methodology 207
Keywords: 209
About GlobalData 210
Contact Us 210
Disclaimer 210
【レポート販売概要】
■ タイトル：薬剤溶出ステントのグローバル製品パイプライン動向2015■ 英文：Drug Eluting Stents (DES) - Pipeline Review, 2015
■ 発行日：2015年3月20日
■ 調査会社：GlobalData
■ 商品コード：GDME0002EPD
■ 調査対象地域：グローバル
- 組み込み分析の世界市場：ダッシュボード＆データ可視化、セルフサービス、ベンチマーク、報告The embedded analytics market is estimated to grow from USD 24.46 Billion in 2016 to USD 46.19 Billion by 2021, at a high Compound Annual Growth Rate (CAGR) of 13.6% during the forecast period. Embedded analytics tools and their applications are gaining traction among the corporates due to the advent of big data and Internet of Things (IoT), increasing dependence on mobile & cloud technologies, an …
- 世界のパイプライン・インフラ安全に関する市場動向（技術進歩、予測、分析：2013-2018）Pipeline safety market report focuses on the security technologies and solutions deployed across pipeline infrastructures (such as pipelines, control units, compressor stations and storage units) to protect them from leakages, physical and cyber attacks. The report is broadly segmented by solutions and technologies such as leakage detection solutions, surveillance solutions, pipeline integrity man …
- 世界の自動車用バンパー市場動向：Global Automotive Bumpers Market 2014-2018TechNavio's analysts forecast the Global Automotive Bumpers market to grow at a CAGR of 4.76 percent over the period 2013-2018. One of the key factors contributing to this market growth is improved safety provided to the vehicles. The Global Automotive Bumpers market has also been witnessing the growing adoption of plastic bumpers. However, the inefficiency issues could pose a challenge to the gro …
- 医療レポート：Hepatitis C Virus-疫学予測（～2022）EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022 Summary Hepatitis C is a largely asymptomatic liver disease caused by the hepatitis C virus (HCV). HCV is an escalating public health problem and burdens an estimated 3% of the world’s population (Trinks et al., 2012). Unlike other acute viral infections that have a rapid onset, HCV infections often persist for decades (CDC, 2013; T …
- Victoria Oil & Gas plc社の石油・ガス開発・生産動向及びコスト分析（2013年）Victoria Oil & Gas plc Oil & Gas Exploration and Production Operations and Cost Analysis - 2013 Summary Victoria Oil & Gas plc Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source f …
- 世界のプロティンエンジニアリング（蛋白質工学）関連市場Proteins exhibit high specificity and less immunogenicity and are widely used as therapeutic agents in the treatment of various disorders and diseases. There are more than 200 protein-based products currently being marketed; 90% of them are used as therapeutics. In order to improve their clinical potential, second generation recombinants are being developed, each exhibiting improved efficiency and …
- 癌免疫療法の世界市場動向Immune system is an intricate network of various tissues, organs and cell that prevents the attack by infectious agents. It prevents the growth and development of pathogens in body that may cause disease development. Wide array of potential disease causing microorganism like bacteria, fungus and virus are identified and eliminated in the body. Immune system also has ability to identify self from f …
- 世界のフレキシブルディスプレイ市場動向（2012-2016）TechNavio's analysts forecast the Global Flexible Displays market to grow at a CAGR of 45.4 percent over the period 2012-2016. One of the key factors contributing to this market growth is the high demand for flexible displays in smartphones and tablet computers. The Global Flexible Displays market has also been witnessing the rapid technological advancement. However, lack of technology standards c …
- 世界の酪農食品（乳製品）市場のニュース及びイベント動向（2014年7月）Synopsis The report provides a review of the latest news and key events in the global dairy food market during July 2014. Summary Using this report, marketers will effectively gain an insight into the latest happenings in the global dairy food market throughout the month. The monthly report provides the reader with the top-line data necessary to quickly keep abreast of latest events in the global …
- Chaparral Energy, Inc.：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Chaparral Energy, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Chaparral Energy, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential sour …
- IoTの世界市場分析：コンポーネント別（デバイス、接続性、ITサービス、プラットフォーム）、用途別（消費者家電、小売、製造、輸送、ヘルスケア）、セグメント予測The Internet of Things (IoT) market was worth USD 605.69 billion in 2014 owing to rising requirement for internet connectivity worldwide coupled with technological advancements. The emergence of start-ups in different industries to satisfy growing need of consumers is anticipated to result in increasing venture capital investments. The market is estimated to grow at 15.2 % to reach over USD 1.88 t …
- 自動車用クーラントの世界市場：有機酸、無機酸、有機酸混合タイプAbout automotive coolants Automotive coolants form an integral part of vehicles and are used in the engines and HVAC systems of the automobiles. They are used to prevent freezing and heating, and provides protection from corrosion. Generally, most of the automotive coolants are made of ethylene glycol, but due to high toxicity of the ethylene glycol, automotive manufacturers are shifting their pre …
- 経頭蓋ドプラ法の世界市場2019-2023About this market The advent of robot-assisted transcranial doppler monitoring is likely to push growth in the market. The recent advances in robotics have led to the emergence of robotically driven transcranial doppler examination probes. These devices help obtain uninterrupted and longer transcranial doppler recordings. Technavio’s analysts have predicted that the transcranial doppler market wil …
- トルコの発電市場2016：市場動向、制度、競争状況Turkey Power Market Outlook to 2030, Update 2016 - Market Trends, Regulations, and Competitive Landscape Summary This report elaborates Turkey's power market structure and provides historical and forecast numbers for generation, capacity and consumption up to 2030. Detailed analysis of the Turkey power market’s regulatory structure, import and export trends, competitive landscape, and power projec …
- Cabot Oil & Gas Corporation：石油・ガスバリューチェーン分析レポート2013Cabot Oil & Gas Corporation Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Cabot Oil & Gas Corporation" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Cabot Oil & Gas Corporation”. The report provides key information relating to oil and gas assets of the company along with its operations across the value c …
